文献速递糖尿病

性别与BMI改变磺脲类与噻唑烷二酮类在2型糖尿病中的获益与风险:基于常规临床与个体试验数据的分层评估框架

Sex and BMI Alter the Benefits and Risks of Sulfonylureas and Thiazolidinediones in Type 2 Diabetes: A Framework for Evaluating Stratification Using Routine Clinical and Individual Trial Data.
PubMed 文献 · Diabetes Care · 2018-08-02

研究基于CPRD、ADOPT、RECORD和GoDARTS数据,评估性别与BMI能否识别磺脲类与噻唑烷二酮类降糖反应及副作用差异。结果显示非肥胖男性磺脲类HbA1c降幅更大,肥胖女性噻唑烷二酮类降幅更大,且噻唑烷二酮类体重增加和水肿风险在肥胖女性中最高。

要点

  • 男性且BMI较低者磺脲类降糖反应更好,噻唑烷二酮类反应较差。
  • 肥胖女性使用噻唑烷二酮类的HbA1c降幅大于磺脲类。
  • 噻唑烷二酮类体重增加和水肿风险在肥胖女性中最高。

核心结论

  • 由性别和BMI定义的患者亚组在噻唑烷二酮类和磺脲类治疗中具有不同的获益与风险模式。
  • 亚组特异性估计可为二甲双胍后个体化选择治疗提供讨论依据。

研究设计与样本

  • 研究纳入CPRD中22,379例起始磺脲类或噻唑烷二酮类治疗的患者,识别与1年HbA1c降幅相关的临床特征。
  • 使用ADOPT试验(一线治疗,n=2,725)和RECORD试验(二线治疗,n=2,222)的个体随机试验数据评估预设亚组的5年血糖反应和副作用。
  • 使用GoDARTS常规临床数据(n=1,977)进行进一步复制。

主要发现

  • 在CPRD中,男性性别和较低BMI与磺脲类血糖反应较大、噻唑烷二酮类反应较小相关(均P < 0.001)。
  • 在ADOPT和RECORD中,非肥胖男性使用磺脲类的总体HbA1c降幅大于噻唑烷二酮类(P < 0.001)。
  • 在ADOPT和RECORD中,肥胖女性使用噻唑烷二酮类的HbA1c降幅大于磺脲类(P < 0.001)。
  • 噻唑烷二酮类的体重增加和水肿风险在肥胖女性中最高。
  • 磺脲类的低血糖风险在所有亚组中相似。

临床怎么用

  • 性别和BMI定义的亚组特异性估计可用于二甲双胍后个体化治疗选择的讨论。
  • 该框架利用常规和共享试验数据,为未来2型糖尿病分层研究提供参考。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The choice of therapy for type 2 diabetes after metformin is guided by overall estimates of glycemic response and side effects seen in large cohorts. A stratified approach to therapy would aim to improve on this by identifying subgroups of patients whose glycemic response or risk of side effects differs markedly. We assessed whether simple clinical characteristics could identify patients with differing glycemic response and side effects with sulfonylureas and thiazolidinediones. RESEARCH DESIGN AND METHODS: We studied 22,379 patients starting sulfonylurea or thiazolidinedione therapy in the U.K. Clinical Practice Research Datalink (CPRD) to identify features associated with increased 1-year HbA1c fall with one therapy class and reduced fall with the second. We then assessed whether prespecified patient subgroups defined by the differential clinical factors showed differing 5-year glycemic response and side effects with sulfonylureas and thiazolidinediones using individual randomized trial data from ADOPT (A Diabetes Outcome Progression Trial) (first-line therapy, n = 2,725) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycemia in Diabetes) (second-line therapy, n = 2,222). Further replication was conducted using routine clinical data from GoDARTS (Genetics of Diabetes Audit and Research in Tayside Scotland) (n = 1,977). RESULTS: In CPRD, male sex and lower BMI were associated with greater glycemic response with sulfonylureas and a lesser response with thiazolidinediones (both P < 0.001). In ADOPT and RECORD, nonobese males had a greater overall HbA1c reduction with sulfonylureas than with thiazolidinediones (P < 0.001); in contrast, obese females had a greater HbA1c reduction with thiazolidinediones than with sulfonylureas (P < 0.001). Weight gain and edema risk with thiazolidinediones were greatest in obese females; however, hypoglycemia risk with sulfonylureas was similar across all subgroups. CONCLUSIONS: Patient subgroups defined by sex and BMI have different patterns of benefits and risks on thiazolidinedione and sulfonylurea therapy. Subgroup-specific estimates can inform discussion about the choice of therapy after metformin for an individual patient. Our approach using routine and shared trial data provides a framework for future stratification research in type 2 diabetes.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Dennis JM, Henley WE, Weedon MN, et al. Sex and BMI Alter the Benefits and Risks of Sulfonylureas and Thiazolidinediones in Type 2 Diabetes: A Framework for Evaluating Stratification Using Routine Clinical and Individual Trial Data. Diabetes Care. 2018. PMID: 30072404. doi:10.2337/dc18-0344

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。